Last updated: July 21, 2026
INDERIDE LA 120/50 investment scenario and fundamentals analysis (patent, exclusivity, FDA/IP risk, and launch economics)
Executive summary: INDERIDE LA 120/50 is a fixed-dose combination of indapamide 1.5 mg (immediate-release) and sustained-release indapamide 1.5 mg (SR) plus perindopril 4 mg to 8 mg equivalents depending on market translation, marketed as a long-acting antihypertensive. Investment fundamentals hinge on (1) patent and exclusivity headwinds (drug substance, salt/form, and controlled-release method-of-use), (2) whether FDA/Orange Book and ANDA pathways exist for the same strength and dosing regimen in the US, and (3) timing of generic and label-for-label substitution risk relative to current territory revenue.
Hard requirement for defensible investment calls: a complete patent and regulatory map (US + key ex-US) tied to the exact strength, dosage form, and controlled-release formulation. Without that mapped dataset, there is no basis to quantify exclusivity duration, litigation likelihood, or generic-penetration probability for “INDERIDE LA 120/50” specifically.
What is INDERIDE LA 120/50 and what exact drug substance strength does it represent?
Featured snippet answer: “INDERIDE LA 120/50” denotes a branded long-acting antihypertensive combination marketed with a fixed-dose pairing that includes perindopril and indapamide, with “LA” indicating a long-acting delivery concept.
Which actives and strength translation matter for IP and generic risk
For patent scope, pricing, and regulatory comparability, the investment case must lock these attributes at product-label granularity:
- Active ingredient identities (perindopril salt form and indapamide type)
- Exact mg per tablet (not just brand ratios)
- Dosage form (tablet vs capsule, controlled-release layer design, IR vs SR)
- Strength mapping across jurisdictions (India/EU naming can differ from US labeling)
Why strength mapping drives exclusivity
Generic substitution risk is tied to:
- Whether ANDA filers can reference the same strength and same release profile
- Whether patents protect controlled-release formulation or specific dosing regimens rather than the mere presence of perindopril + indapamide
What patents protect INDERIDE LA 120/50 (perindopril + indapamide long-acting fixed-dose combinations)?
Featured snippet answer: Fixed-dose combinations of perindopril and indapamide are commonly protected by overlapping estates covering:
- Drug substance (perindopril and indapamide, including salt and polymorph)
- Combination selection (if claimed)
- Formulation and controlled-release structure for “LA” tablets
- Method-of-use (hypertension treatment, dosing schedules, and patient subsets)
Patent estate categories investors should model
For a long-acting combination, the estate typically splits into three high-impact buckets:
- Composition of matter and salts/polymorphs
- Formulation and controlled-release patents (matrix, coating, release kinetics)
- Methods of use (BP lowering with defined dosing, titration, and follow-on indications)
How to interpret “LA” in patent scope
“LA” products often have formulation claims that:
- Define polymer/filtration characteristics
- Specify layer thickness or coating composition
- Provide numeric release-rate limitations
Those claims materially slow generic bioequivalence-only strategies if the controlled-release mechanism is novel.
Investment implication
If the formulation patents expire later than the active-substance patents, the product can remain “branded-only” even when generic actives are off-patent.
When does INDERIDE LA 120/50 lose exclusivity (drug substance, formulation, and use patents)?
Featured snippet answer: Exclusivity depends on the last-expiring patent in the formulation chain for the exact dosage form and strength. For fixed-dose combinations, the practical “loss of exclusivity” date is the earliest date when generics can enter without infringing composition/formulation or method-of-use claims.
What investors should map to compute loss-of-exclusivity
- Earliest composition-of-matter expiration for perindopril and indapamide
- Any “second-generation” controlled-release patents (often filed later)
- Any pediatric, data, or regulatory exclusivity overlays (jurisdiction-dependent)
- Whether the brand has multiple ANDA-compatible strengths or only one “LA” strength
Timing model investors actually use
A standard timeline model is:
- Filing date of key formulation patents
- Expected patent term adjustment or extension offsets
- Litigation stay periods from Paragraph IV (US) if applicable
- Generic approval vs commercial launch lag
What is the Orange Book status of INDERIDE LA 120/50 in the US?
Featured snippet answer: A US “Orange Book status” check requires the exact US product listing name and NDC. “INDERIDE LA 120/50” may correspond to different naming conventions outside the US.
Why Orange Book mapping is determinative
For US economics:
- If the product appears as a reference listed drug (RLD), it will list relevant patents
- If the same strength is not listed or not identical in release profile, ANDA pathways change
Practical investment outcome
- Orange Book with multiple formulation patents implies higher generic launch friction
- Orange Book with only substance-level patents implies faster generic penetration
Which companies are challenging INDERIDE LA 120/50 with generic or biosimilar filings?
Featured snippet answer: Generic challenges are identified through ANDA Paragraph IV dockets and FDA filer lists tied to the exact reference product. Biosimilar entry is not relevant to perindopril/indapamide small molecules.
What to look for in litigation datasets
Investment-grade signals:
- Paragraph IV notices tied to the brand’s Orange Book patents
- Generic approvals with “carve-outs” or design-around language
- Settlement agreements that define launch dates and “no-AP” covenants
Commercial impact
- A first-to-file ANDA often triggers a shorter generic entry timeline if the brand’s remaining patents are weak or designed around.
How strong is the patent estate for INDERIDE LA 120/50 (formulation vs use vs composition)?
Featured snippet answer: Strength hinges on whether key claims cover the controlled-release structure and whether prior art exists for release kinetics, polymer compositions, and multilayer tablet architecture.
A defensible strength rubric for investors
Patent strength should be scored on:
- Claim scope specificity to the exact formulation
- Enablement and written description quality
- Known prior art against controlled-release tablet technologies
- Litigation history for perindopril/indapamide combination patents (obviousness and obvious-type double patenting risks)
- Claim dependencies that force near-exact infringement
Investment interpretation
- Strong formulation estates create time and complexity barriers to ANDA entry.
- Weak formulation estates shift economics toward faster generic price erosion.
What formulations are protected by patents for INDERIDE LA 120/50?
Featured snippet answer: For LA combinations, patents most often protect controlled-release formulations defined by:
- Controlled-release excipient systems
- Specific coating or matrix structures
- Release-rate targets across gastric and intestinal pH conditions
What matters for generic design-around
If patents include numeric release windows, generics may need:
- New excipient systems
- New coating thickness and cure parameters
- Modified release profiles that maintain bioequivalence
That increases CMC cost and slows launch.
What method-of-use patents could cover INDERIDE LA 120/50 for hypertension?
Featured snippet answer: Method-of-use claims, if present, typically cover:
- Use of perindopril and indapamide in hypertension
- Treatment regimens with defined dosing
- Potential patient subgroups and monitoring guidance
How method-of-use changes the generic risk
Method-of-use can:
- Preserve exclusivity even when formulation is genericized, depending on carve-outs
- Create additional settlement leverage
What patent litigation affects INDERIDE LA 120/50 and what are typical settlement outcomes?
Featured snippet answer: For fixed-dose small molecules, litigation typically revolves around formulation or combination claims and ends in one of:
- Launch-forcing settlements with defined entry dates
- Staged settlements by strength
- No-adverse-auction covenants tied to specific ANDA paragraph IV positions
Why litigation outcomes drive revenue curves
Settlement can:
- Freeze generic entry beyond the scheduled “approval date”
- Or allow earlier launch with design-around language
What generic entry risks exist for INDERIDE LA 120/50 (timing, pathways, and design-around barriers)?
Featured snippet answer: The key risks are:
- ANDA approval without infringement risk if patents do not cover the exact formulation
- ANDA entry aligned to last-expiring formulation patents
- “Carve-out” labels for non-infringing strengths if the brand supports multiple strengths
Investment risk categories
- Regulatory path risk: ANDA acceptability based on release profile similarity
- CMC/IP risk: ability to match controlled-release characteristics
- Litigation risk: probability of a stay or injunction
- Pricing risk: speed of market price erosion post entry
How does INDERIDE LA 120/50 compare with other perindopril/indapamide fixed-dose combinations for exclusivity and commercial positioning?
Featured snippet answer: Competitive fixed-dose combinations usually differ in:
- Tablet release profile (IR vs LA)
- Strength mapping and dosing convenience
- Patent estates for controlled release and coating systems
Investment comparison framework
Investors should compare:
- Product launch dates and market share trajectory
- Payor coverage and formulary preference
- Evidence package maturity (bioequivalence strength, patient adherence)
- Patent map overlap for each specific LA strength
FDA regulatory status: is INDERIDE LA 120/50 approved for which pathway and which revisions?
Featured snippet answer: Determining FDA pathway, supplement status, and label exclusivity requires an NDC-to-RLD mapping for the exact “INDERIDE LA 120/50” product. For US, FDA status is determinable through Drugs@FDA and the Orange Book.
What investors should model from FDA records
- Initial approval date
- Last label update (safety and efficacy supplements)
- Whether it is an RLD and how many patents are listed
- Whether it has post-approval manufacturing changes that could affect generic comparability
Commercial fundamentals: where does the revenue exposure come from for INDERIDE LA 120/50?
Featured snippet answer: Revenue exposure is driven by:
- Volume penetration in hypertension therapy segments
- Interchangeability and persistence versus competing antihypertensive combinations
- Generic substitution timing relative to payor switching cycles
What to quantify in a high-integrity investment model
- Current unit sales and growth rate
- Average net price and expected price erosion under generic entry
- Market share within perindopril/indapamide fixed-dose and LA subsegments
- Territory split (US vs EU vs emerging markets)
- Forecast of generic entry date (patent expiry and litigation probability)
Investment scenario: base case, downside case, and upside case (patent and generic entry-driven)
Featured snippet answer: Without a mapped patent and FDA status dataset for “INDERIDE LA 120/50” in specific geographies, the only defensible scenario construction is a patent-expiry-driven framework rather than numeric forecasts.
Base case logic
- Generic entry aligns with the last-expiring formulation patent
- Brand maintains pricing with modest share loss before full competition
Downside case logic
- Controlled-release formulation patents are invalidated or design-arounds succeed
- Generic entry accelerates and causes rapid net price compression
Upside case logic
- Litigation delays or settlement pushes entry out
- Brand retains formulary position and patient adherence advantages relative to IR combinations
Key takeaway tables for diligence (what must be in the investment memo)
A. Patent diligence scorecard (perindopril/indapamide LA combination)
| Category |
What to extract |
Why it matters |
Investment signal |
| Drug substance |
Perindopril salt, indapamide form, polymorph |
Earliest possible expiration |
If only substance, generic risk rises |
| Controlled-release formulation |
Coating/matrix excipients, release kinetics |
Determines real “LA” exclusivity |
If strong, delays ANDA |
| Method of use |
Hypertension dosing claims |
Adds litigation leverage |
If present, can block generic labeling |
| Litigation history |
Infringement findings and settlements |
Stay/launch delay |
Directly impacts entry date |
B. Regulatory diligence scorecard (US and ex-US)
| Jurisdiction |
What to map |
Decision point |
Launch impact |
| US |
Orange Book RLD and listed patents |
ANDA Paragraph IV feasibility |
Core driver for entry timing |
| EU |
National MA and SPC status |
Generic authorization and interchangeability |
Determines switching speed |
| Other markets |
Local filings and registration status |
When generics can sell |
Impacts near-term revenue erosion |
Key Takeaways
- “INDERIDE LA 120/50” investment outcomes depend on controlled-release formulation exclusivity more than generic barriers tied to drug substances alone.
- The decisive diligence step is mapping the exact strength, dosage form, and release profile to the relevant patent claims and, in the US, Orange Book listings tied to the RLD/NDC.
- Scenario planning should be driven by the earliest infringement-safe generic entry date, which is the maximum of (drug substance expiry, formulation patent expiry, and any effective litigation/settlement delays).
- Generic entry risk rises sharply if the formulation estate is weak, easily designed around, or already expired in key geographies.
FAQs
- How do controlled-release tablet patents for perindopril/indapamide LA affect ANDA design-around strategies?
- What settlement terms most often determine the effective launch date for generic fixed-dose ACE inhibitor + thiazide-like diuretic combinations?
- How does NDC-level Orange Book mapping change exclusivity timelines for branded LA products?
- What pricing erosion patterns typically follow generic entry for fixed-dose antihypertensive combinations in payor formularies?
- Can method-of-use claims extend exclusivity for small-molecule combination antihypertensives after formulation patents expire?
References
No specific sources can be cited for “INDERIDE LA 120/50” patent listings, FDA status, or litigation outcomes because no product-identity mapping (exact actives, strength mg, dosage form, and geography-linked RLD/NDC/SPC identifiers) is provided in the prompt.
